Overview
Patients with large B cell lymphoma (LBCL) have a number of choices of front line (1L) therapies; however, relapsed and refractory disease are common, suggesting there is an unmet need for treatments in later line settings. This study examined 10,016 LBCL patients from the US nationwide Flatiron Health electronic health record-derived deidentified database to understand treatment patterns and identify factors linked to death before starting second-line (2L) therapy.
About 18% of patients died within 12 months of 1L completion without starting 2L therapy, and only 30% began 2L treatment. Factors such as poor performance status, advanced disease, and lower socioeconomic status predicted higher mortality. These findings highlight the urgent need for improved and timely treatments in the 1L setting to prevent early death and improve outcomes.
Why this matters
Through real-world data, these findings identified a gap in current treatment options for adult patients with large B cell lymphoma and highlighted key factors that predict death before 2L, including factors associated with a patient's International Prognostic Index (IPI), and their socio-economic status. This research also provides clear opportunities for future research that may improve outcomes for patients with LBCL.